NCT06909825 2026-05-06FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Fusion Pharmaceuticals Inc.Phase 2 Active not recruiting85 enrolled